High-dose methylprednisolone pulse therapy during refractory COVID-19 acute respiratory distress syndrome: a retrospective observational study.

MLA

Zeiner, Carsten, et al. “High-Dose Methylprednisolone Pulse Therapy during Refractory COVID-19 Acute Respiratory Distress Syndrome: A Retrospective Observational Study.” BMC Pulmonary Medicine, vol. 23, no. 1, Oct. 2023, pp. 1–6. EBSCOhost, https://doi.org/10.1186/s12890-023-02664-5.

APA

Zeiner, C., Schröder, M., Metzner, S., Herrmann, J., Notz, Q., Hottenrott, S., Röder, D., Meybohm, P., Lepper, P. M., & Lotz, C. (2023). High-dose methylprednisolone pulse therapy during refractory COVID-19 acute respiratory distress syndrome: a retrospective observational study. BMC Pulmonary Medicine, 23(1), 1–6. https://doi.org/10.1186/s12890-023-02664-5

Chicago

Zeiner, Carsten, Malte Schröder, Selina Metzner, Johannes Herrmann, Quirin Notz, Sebastian Hottenrott, Daniel Röder, Patrick Meybohm, Philipp M. Lepper, and Christopher Lotz. 2023. “High-Dose Methylprednisolone Pulse Therapy during Refractory COVID-19 Acute Respiratory Distress Syndrome: A Retrospective Observational Study.” BMC Pulmonary Medicine 23 (1): 1–6. doi:10.1186/s12890-023-02664-5.